Balipodect PDE10A Inhibition for Disease-Modifying ASD Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a disease-modifying therapy for autism spectrum disorders (ASDs) such as CDKL5 deficiency disorder and Fragile X syndrome, as well as treatments for non-seizure symptoms and refractory seizures in these conditions.
Innovation Solution
The use of a PDE10A inhibitor, specifically Compound A, to treat or prevent autism spectrum disorders by administering an effective amount of the inhibitor to a mammal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current medications and behavioral therapy are used for autism spectrum disorders, then some symptoms can be managed, but there is no disease-modifying therapy available and refractory seizures remain untreated
Solution Approach 1:
The patent changes the biochemical parameter by inhibiting PDE10A enzyme activity, thereby increasing cGMP levels in the brain. This parameter change leads to disease-modifying effects in ASD models, addressing the lack of curative therapy while maintaining compatibility with existing treatment approaches.
2Reliability
If PDE10A inhibitor is administered to treat autism spectrum disorders, then motor deficits and behavioral symptoms are improved, but potential side effects and drug development complexity arise
Solution Approach 1:
The patent uses PDE10A inhibition as an intermediary mechanism to increase cGMP levels, which then acts as a mediator to improve motor deficits and behavioral symptoms. This indirect approach through a specific enzymatic target provides a more controlled and selective treatment pathway compared to direct neurotransmitter manipulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Compound A has shown potential in normalizing motor deficits and improving behavioral symptoms in CDKL5 deficiency disorder and Fragile X syndrome mouse models, indicating its efficacy in treating these conditions.
Implementation Method 1
Phosphodiesterases (PDEs) are a superfamily of enzymes encoded by 21 genes and subdivided into 11 distinct families according to structural and functional properties. These enzymes metabolically inactivate the ubiquitous intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP)
Data Source
AI summary
The invention is the use of a PDE10A inhibitor to treat or prevent autism spectrum disorders. More particularly, a method of treating or preventing an autism spectrum disorder selected from the group consisting of autistic disorder, CDKL5 deficiency disorder, childhood disintegrative disorder, Rett syndrome, Fragile X syndrome, Kleefstra syndrome, Pitt Hopkins syndrome, Angelman syndrome, Kabuki syndrome, Asperger's syndrome, Heller's syndrome and Pervasive Developmental Disorder, comprising administering an effective amount of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one or a salt thereof to a mammal. Additionally, a medicament for the treatment or prevention of autism spectrum disorders, and the use of a PDE10A inhibitor in the manufacture of a medicament for the treatment or prevention of autism spectrum disorders.